Medication for OCD: What Works, How Long It Takes, and What to Try Next

Labyrinth Psychiatry Group · Published October 23, 2026 · FDA labels and device records read that day · Clinical review by Dr. Salvatore G. Savatta pending

The short answer

Five medicines are FDA-approved for OCD: clomipramine (Anafranil), fluoxetine (Prozac), fluvoxamine, paroxetine (Paxil) and sertraline (Zoloft). Four are SSRIs (selective serotonin reuptake inhibitors). Clomipramine is an older tricyclic antidepressant. Most people start with an SSRI. For OCD, the dose is often higher and the wait longer than for depression: NIMH says 8 to 12 weeks before symptoms begin to improve. With any one SSRI, about 40% to 60% of people improve meaningfully, according to the International OCD Foundation. If the first one does not work, there is a well-worn path of next steps, set out below.

What OCD is, and what medicine is meant to do

OCD means unwanted, repeated thoughts, urges or images (obsessions) and repeated actions or mental acts done to ease the distress (compulsions). NIMH notes that people with OCD usually spend more than an hour a day on them and cannot control them, even when they know they are excessive. About 1.2% of US adults have OCD in a given year, and 2.3% at some point in their lives.

Medicine does not cure OCD. It turns down the volume, so obsessions are less intense and rituals are easier to resist. The ADAA describes its main job as making therapy easier to do. The American Psychiatric Association calls SSRIs and ERP therapy the two first-line treatments and says severe OCD should get both at once.

The FDA-approved medicines for OCD, side by side

Each row comes from that drug’s current FDA label on DailyMed, read October 23, 2026. Doses are the label’s, for orientation only; your prescriber sets yours. On a phone, each medicine reads top to bottom.

Common medicines that are not FDA-approved for OCD

Doctors may still prescribe these for OCD (that is called off-label use), but OCD is not a listed use on their current labels:

• Escitalopram (Lexapro). The label lists major depression and generalized anxiety disorder.
• Citalopram (Celexa). The label lists major depression in adults.
• Paroxetine extended-release (Paxil CR). The label lists major depression, panic disorder, social anxiety disorder and PMDD.
• Aripiprazole (Abilify). The label lists schizophrenia, bipolar I mania, add-on treatment for major depression, irritability with autism, and Tourette’s.
• Risperidone (Risperdal). The label lists schizophrenia, bipolar I mania and irritability with autism.

The American Psychiatric Association still lists escitalopram among the SSRIs used for OCD. It does not recommend citalopram for OCD, because its firm dose limit is often too low for OCD.

Why OCD needs higher doses and more time

OCD tends to respond at the top of the dose range, and slowly. The International OCD Foundation says doses up to two to three times those used for depression and anxiety tend to give the most benefit. The labels show the same pattern:

• Fluoxetine. The Prozac label says 20 mg a day is enough for most people with depression, but recommends 20 to 60 mg a day for OCD, and says the full effect may be delayed until 5 weeks or longer.
• Sertraline. In two of the adult OCD trials on the Zoloft label, people who finished averaged about 185 mg a day, near the 200 mg maximum.
• Fluvoxamine. The label trials used 100 to 300 mg a day, with doses above 100 mg split into two.

What a full trial looks like

• NIMH: 8 to 12 weeks before symptoms begin to improve.
• American Psychiatric Association: improvement often takes 6 to 12 weeks; try an SSRI for at least 12 weeks, every day, at a high enough dose.
• International OCD Foundation: an adequate trial is 8 to 12 weeks, with at least 6 of them at the moderate to high doses OCD needs. Improvement can keep coming after week 12.

The IOCDF warns that many SSRI trials are called failures when the dose was too low or the trial too short. That is the first thing to check before switching.

How much it helps

In the Anafranil label’s trials, adults on clomipramine saw their OCD severity score (the Y-BOCS) fall 35% to 42% on average, while people on placebo showed no important response. For SSRIs, the IOCDF says those who respond see symptoms drop by 40% to 50% on average. Improvement, not a cure, is the usual result, and that is why medicine is so often paired with ERP.

If the first medicine doesn’t work: the usual next steps

Expert groups describe much the same sequence. This is the general order, drawn from the APA, NIMH and the IOCDF. Your psychiatrist may change the order to fit your history.

1. Start an SSRI and raise it to an OCD dose. The American Psychiatric Association says SSRIs are a first-line treatment, at doses often higher than for depression.
2. Give it a full trial. NIMH says 8 to 12 weeks before symptoms begin to improve. The APA says to try it for at least 12 weeks, taken every day, at a high enough dose.
3. Add or step up ERP therapy. Exposure and response prevention is the other first-line treatment, and NIMH says it works even for some people who do not respond well to medication.
4. Switch to a second SSRI. The IOCDF notes that people often respond to a second SSRI, though somewhat less often than to the first.
5. Try clomipramine or an add-on medicine. After one or two SSRI trials, the IOCDF lists switching to clomipramine or adding a second medicine, most often a low-dose antipsychotic.
6. Ask about TMS. Several TMS systems are FDA-cleared as an add-on treatment for adults with OCD, alongside medicine, therapy or both.

Clomipramine: effective, with more to watch

According to the IOCDF, clomipramine was the first medicine FDA-approved for OCD. It says head-to-head trials found it no more effective than SSRIs for adults, but it can work for some people SSRIs did not help. It has more side effects. The Anafranil label lists dry mouth, constipation, nausea, sleepiness, tremor, dizziness, sweating, weight gain and sexual side effects among the most common. It also names seizures as the most significant risk: about 0.64% of people had one by 90 days and 1.45% by one year, at doses up to 300 mg a day. The IOCDF advises blood-level checks and regular EKGs for people taking it.

Add-on medicines (augmentation)

Adding a second medicine to an SSRI is common when one or two SSRI trials help only partly. The IOCDF says the best-studied add-ons are low doses of the antipsychotics aripiprazole and risperidone, and that about one in three people who did not respond to an SSRI alone respond when one is added. These are off-label: OCD is not a listed use on the Abilify or Risperdal labels. Antipsychotics alone, without an SSRI, do not treat OCD. Other add-ons under study include memantine, N-acetylcysteine, lamotrigine and topiramate.

Ondansetron, an anti-nausea medicine, is another add-on in research. The IOCDF says numerous placebo-controlled trials found that adding ondansetron or granisetron to an SRI helped some people who had not responded to the SRI alone. In a trial reported in 2025 by the Brain & Behavior Research Foundation (51 people finished; 24 mg a day for 4 weeks), ondansetron did not lower OCD severity overall compared with placebo, but people with OCD who were also taking an SRI improved significantly more. Its FDA label covers only the prevention of nausea and vomiting, so any OCD use is off-label.

Other antidepressants come up too. ADAA experts note that SNRIs, such as venlafaxine, are sometimes considered when SSRIs do not help or cause hard side effects, though the evidence for them in OCD is not as strong.

One thing the ADAA says not to rely on: sedatives such as benzodiazepines. They may calm anxiety quickly, but they can be habit-forming and can undercut what ERP teaches.

ERP therapy, the other first-line treatment

Exposure and response prevention (ERP) is a type of cognitive behavioral therapy. You face the things that trigger obsessions, in planned steps, and practice not doing the ritual. NIMH says ERP reduces compulsions even for some people who do not respond well to medication. The APA says mild to moderate OCD can be treated with ERP, an SSRI or both, and severe OCD with both together. Medicine and ERP are partners, not rivals: the medicine often makes ERP easier to start.

TMS for OCD: the next step after medicine and therapy

Transcranial magnetic stimulation (TMS) uses a magnetic coil held against the head to stimulate brain areas linked to OCD. You stay awake, nothing is implanted and no anesthesia is used. In 2018 the FDA permitted the first TMS system for OCD, and NIMH notes that in 2022 the clearance was extended to standard TMS devices. In the trial behind the first clearance (100 patients who stayed on their usual OCD treatment), 38% responded to real TMS versus 11% to a sham device. The most common side effect was headache, in about the same share of both groups.

These are the TMS systems with an FDA record for OCD, found in the FDA’s 510(k) and De Novo databases under product code QCI. Each is cleared as an add-on for adults with OCD, not as a replacement for medicine or therapy. The list includes BrainsWay’s deep TMS and systems from other makers, such as NeuroStar (K212289, 2022); NIMH describes the 2022 clearance as extending OCD use to standard TMS devices.

What a course looked like in the trial behind the first clearance, per the FDA decision summary: sessions every weekday for 6 weeks, a follow-up visit 4 weeks later, and, before each session, up to 5 minutes of tailored symptom provocation to activate the OCD circuits. People stayed on their usual OCD treatment, at a stable dose for 2 months before the trial.

Labyrinth’s TMS page lists OCD among the conditions it treats, with a course of 30 sessions for OCD, five a week. This article does not say which TMS system Labyrinth uses. The FDA’s 2018 announcement lists who should not have that device, including people with metal objects or implanted stimulators in or near the head; Labyrinth’s TMS page lists its own safety screening.

Deep brain stimulation, for the most severe cases

The FDA allows one deep brain stimulation system, Medtronic’s Reclaim, under a Humanitarian Device Exemption (2009). It is limited to adults with chronic, severe OCD who have failed at least three SSRIs, as an add-on to medicines. It is brain surgery, and NIMH calls it experimental. Labyrinth does not list it.

Safety: what every OCD medicine label warns about

• Suicidal thoughts in young people. All antidepressants carry a boxed warning. The Zoloft label, for example, says antidepressants increased suicidal thoughts and behaviors in children and young adults in short-term studies; its medication guide names people 24 and younger, especially early in treatment or after a dose change.
• Serotonin syndrome. The risk rises when two serotonin-raising medicines are combined. Tell your prescriber about everything you take, including supplements.
• Stopping. Stopping suddenly can cause discontinuation symptoms such as dizziness, irritability, nausea and electric-shock sensations. The label recommends lowering the dose gradually.
• How long to stay on it. The ADAA says treatment often lasts at least 1 to 2 years before tapering is considered. The IOCDF says relapse is common after stopping, and ERP can lower that risk.

Insurance for OCD medication visits and TMS

For what psychiatry visits, including medication follow-ups, can cost in New Jersey with and without insurance, see how much a psychiatrist costs in NJ. TMS for OCD is harder: Aetna’s TMS policy (last reviewed July 17, 2026), for example, lists obsessive-compulsive disorder among the uses for which it considers TMS experimental, investigational or unproven. Other plans set their own rules, so check yours. Labyrinth’s TMS page lists Aetna, Blue Cross Blue Shield, Cigna, Medicare, TRICARE and UnitedHealthcare/Oxford, and says the list is not a guarantee of coverage. More detail: how much TMS costs in New Jersey.

OCD medication care at Labyrinth in Cranford

Labyrinth Psychiatry Group’s OCD page describes an evaluation that looks at your symptoms, their impact and what you have already tried, before a plan is discussed. The plan may include medication management, psychotherapy (usually CBT, of which ERP is a part) and TMS, with telehealth and in-person visits. The office is at 11 Commerce Drive, Lobby Floor, Cranford, in Union County.

If you are already on a medicine for OCD and it has not done enough, bring the details: each medicine, the highest dose, how many weeks you took it, and any side effects. That history is what tells a psychiatrist whether you have had a full trial and what to try next.

Questions to bring to the evaluation

1. Is my current dose in the range used for OCD, and how many weeks have I been at that dose?
2. Have I had a full trial of one SSRI, or two?
3. If we switch or add a medicine, what side effects and check-ups come with it?
4. Could ERP therapy be added, and is it done here or by referral?
5. Am I a candidate for TMS for OCD, and what would my plan need before it covers it?
6. How long should I stay on the medicine once it works, and how would we taper it later?

Call 908-336-1187 or use the evaluation request form. Please keep health details, such as diagnoses, symptoms and medicines, out of the online form; bring them to the visit. Office staff follow up to arrange a time.

Questions about medication for OCD